Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients With Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH-OUTCOMES)

Next Previous
Trial Profile

A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients With Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH-OUTCOMES)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Resmetirom (Primary)
  • Indications Fibrosis; Liver cirrhosis; Non-alcoholic steatohepatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms MAESTRO-NASH OUTCOMES
  • Sponsors Madrigal Pharmaceuticals

Most Recent Events

  • 29 Apr 2025 According to a Madrigal Pharmaceuticals media release, data from this trial to be presented at the upcoming European Association for the Study of the Liver (EASL) Congress, taking place from May 7-10, 2025, in Amsterdam, the Netherlands.
  • 26 Feb 2025 According to a Madrigal Pharmaceuticals media release, data are anticipated in 2027
  • 30 Oct 2024 According to a Madrigal Pharmaceuticals media release, data from this trial to be presented in presentations at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting, taking place from Nov 15-19, 2024 in San Diego.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top